The Patent Finder
AP

Araxes Pharma LLC

First filing 2014
OverviewNotableFeesChangesFamiliesPatent listSources & methods

36 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next US patent term in the Araxes Pharma LLC portfolio ends in Mar 2034, and more of its terms end in 2034 (13) than in any other year. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2034
Next term end
25
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Covalent Inhibitors of Kras G12C US 9,227,978
Cited by 152 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Ends Mar 2034 · High confidence
Also notable
Substituted Quinazolines as Inhibitors of Kras G12C US 9,840,516
The most cited patent in this portfolio, cited by 180 later US patents, top 5% of utility patents granted in 2017 in our data. Protection runs to 2034.
Ends Oct 2034 · High confidence
Also notable
Covalent Inhibitors of Kras US 10,745,385
Cited by 51 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2038.
Ends May 2038 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 16, 2027
    The maintenance fee for Substituted Quinazoline Compounds and Methods of Use Thereof (US 10,351,550) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
  • 2 fees due Feb 6 to 13, 2027 · next Feb 6
  • 1 fee due Mar 17, 2027
    The maintenance fee for 2-Substituted Quinazoline Compounds Comprising a Substituted Heterocyclic Group and Methods of Use Thereof (US 10,414,757) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
  • 1 fee due Apr 1, 2027
    The maintenance fee for Fused-Tricyclic Inhibitors of Kras and Methods of Use Thereof (US 10,428,064) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.
  • 2 fees due Jul 5 to 23, 2027 · next Jul 5
  • 2 fees due Nov 12, 2027

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 9,227,978Covalent Inhibitors of Kras G12C
In force
 · High confidence
In forceHigh confidence
US 9,926,267Covalent Inhibitors of Kras G12C
In force
 · High confidence
In forceHigh confidence
US 10,273,207Covalent Inhibitors of Kras G12C
In force
 · High confidence
In forceHigh confidence
US 10,882,847Inhibitors of Kras G12C Mutant Proteins
In force
 · High confidence
In forceHigh confidence
US RE50,527Covalent Inhibitors of Kras G12C
In force
 · Low confidence
In forceLow confidence
US 9,840,516Substituted Quinazolines as Inhibitors of Kras G12C
In force
 · High confidence
In forceHigh confidence
US 10,111,874Combination Therapies for Treatment of Cancer
In force
 · High confidence
In forceHigh confidence
US 10,144,724Substituted Quinazoline Compounds and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 10,351,550Substituted Quinazoline Compounds and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 10,370,386Substituted Quinolines as Inhibitors of Kras G12C
In force
 · High confidence
In forceHigh confidence
10 of 36 patents shown.
Pro members see all 36.
Pro members: see all 36 patents
Also on record, not counted in the 36: 10 patents ended · 4 applications pending · 12 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited